This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 594| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2501 | NMNAT3, OASL, TMPRSS3, MFSD7, AEBP1, UBD, S100A4, C1orf151, CRIP1, ASCC3, ZNF271, ANXA4, NMI, UBE2L6, B2 M, HLA-F, PSMB9, TAP1, PSME2, IFI16, IFI27, ARHGAP9, RABGAP1L, TNK1, DEF6, BTN3A3, RPS6KA1, CD24, PARP10, APOL3, STAT, ANKRD10, CKB, H2AFZ, PSMB9, RARRES3, RGS10, TUBB, NOL3, CD7, | RNAs | Human | Upregulated in HCV related non-HCC than normal control (With 3-fold change) | Diagnostic | HCV related non-HCC v/s normal control | p < 0.01 | Tissue | 19821982 |
| 2502 | CAPG, OCC-1, EED, RPLP0, RPLP0P2, AP1S2, RRAGD, PFDN4, CCDC104, C7orf28B, PSIP1, LPCAT1, FSCN3, RAB24, ZNF446, SEC11B, ZNF586, SCNM1, SF3A1, RUFY1, TRIM55, GOLGA4, GPATCH4, THOP1, TUBB2C, PHLDB3, FAM104A, FASTK, EIF2AK4, ZFP41, PRKRIP1, DSTN, PHIP, NUCKS1, TNRC8, CCDC132, EPRS, HIST1H4C, CDCA8, | RNAs | Human | Upregulated in HCV related HCC than HCV related non-HCC (With 3-fold change) | Diagnostic | HCV related HCC v/s HCV related non-HCC | p < 0.01 | Tissue | 19821982 |
| 2503 | Fibronectin, Tubulin-alpha-1 subunit, Matrix metalloproteinase 14, osteonectin SPARC, RAD23A, Ubiquitin-conjugating enzyme E2, Neutrophil-gelatinase associated lipocalin precursor lipocalin 2, TRAM protein, ADP/ATP carrier protein, High mobility group protein, Insulin stimulated protein kinase 1, Tr | RNAs | Human | Diffrenetially expressed in HCC v/s non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 11973655 |
| 2504 | CDC28 protein kinase2, CDC27HS protein, Integrin beta 4, Desmoplakin 1/2, Procollagen C proteinase, platelet derived growth factor, cytidine deaminase, aminoacyalse1, Betaine homocysteine S-methyltransferase, methylenetetrahydrofolate dehydrogease, metalloproteinase inhibitor1, aldehyde oxidase, met | RNAs | Human | Diffrenetially expressed in HCV and HBV associated HCC v/s non-tumor | Diagnostic | HCV and HBV associated HCC v/s non-tumor | p < 0.01 | Tissue | 11973655 |
| 2505 | Lactate dehydrogenase, aldehyde oxidase, nucleoside diphosphate kinase, alpha 1 catenin, beta catenin, transforming protein rho B, IgG, IgGK, IgG3, IgG1, IgG1K, IgA1, IgHA, IgG1-Fc, Collagen - alpha 1 subunit, c-jun N-terminal kinase 2, ADP/ATP carrier protein, Progression receptor associated protei | RNAs | Human | Diffrenetially expressed in cirrhotic v/s non-cirrhotic | Diagnostic | cirrhotic v/s non-cirrhotic | p < 0.01 | Tissue | 11973655 |
| 2506 | Zinc finger protein, integrin alpha 6, hepatoma derived growth factor, TGF beta induced, Macrophage inhibitory cytokine 1, lymphocyte antigen, aldehyde oxidase, c-myc purine binding transcription factor puf, plasminogen, vitronectin, hemoglobin alpha subunit, cytosolic superoxide dismutase, methylen | RNAs | Human | Diffrenetially expressed in moderately differentiated HCC v/s poorly differentiated HCC | Diagnostic | moderately differentiated HCC v/s poorly differentiated HCC | p < 0.01 | Tissue | 11973655 |
| 2507 | SGCE | RNAs | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 19171046 |
| 2508 | PEG10 | RNAs | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 19171046 |
| 2509 | CCL20, S100P, PEG10, SGCE, XAGE-1, COL4A1, ZNF83, and TM4SF1 | RNAs | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 19171046 |
| 2510 | FGL2 | Protein | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 18715028 |
| 2511 | MYADM | Protein | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 18715028 |
| 2512 | GC | Protein | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 18715028 |
| 2513 | OTC | Protein | Human | Downregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 18715028 |
| 2514 | FGL2, GC, FLNA, FHL1, FBN2, TLN1 | Protein | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 18715028 |
| 2515 | OTC, PEBP1, FABP1, CPS1, ARG1, EPHX1 | Protein | Human | Downregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 18715028 |
| 2516 | MT1G | Protein | Human | Downregulated in HCC than non-tumor (with 100 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.001 | Tissue | 16980951 |
| 2517 | FGG | Protein | Human | Downregulated in HCC than non-tumor (with 100 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 16980951 |
| 2518 | FGL1 | Protein | Human | Downregulated in HCC than non-tumor (with 100 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 16980951 |
| 2519 | Alpha-2-plasmin inhibitor, SERPINF2 | Protein | Human | Downregulated in HCC than non-tumor (with 100 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 16980951 |
| 2520 | Gain of Chromosome 7 | Copy Number variation | Human | Chromosome 7 median copy number > 2.2 associated with early recurrence (within 2 years) in HCC (with Hazard ratio 5.8) | Prognostic | Early recurrence v/s late recurrence | p < 0.001 | Tissue | 18701503 |
| 2521 | Gain of Chromosome 7 | Copy Number variation | Human | Chromosome 7 median copy number > 2.2 associated with overall recurrence in HCC (with Hazard ratio 3.4) | Prognostic | Early recurrence v/s late recurrence | p < 0.001 | Tissue | 18701503 |
| 2522 | BIC, CPNE1, RBPMS, RFC4, RPSA, TOP2A | RNAs | Human | Upregulated in dedifferentiated HCC (with fold change > 2.6) | Diagnostic | moderately and well differentiated HCC v/s low-differentiated HCC | FDR < 2%. | Tissue | 18820673 |
| 2523 | MT1G, MT1F | RNAs | Human | Downregulated in dedifferentiated HCC (with fold change of > 0.35) | Diagnostic | moderately and well differentiated HCC v/s low-differentiated HCC | FDR < 5%. | Tissue | 18820673 |
| 2524 | HIF1A | RNAs | Human | Upregulated in 17 HCC patients ( with fold change 2.14, ±0.93) and downregulated in 36 HCC patients (with fold change 0.75, ±0.26) in the HCC compared to corresponding non-malignant liver tissue | Prognostic | HCC v/s non-tumor; predict recurrence of HCC in patients | p < 0.001 | Tissue | 20165955 |
| 2525 | Cytoplasmic dynein light chain, Hepatoma-derived growth factor, Ribosomal protein L6, glutathioneS-transferase, Fibronectin, Ras homolog gene family member B, TR3 orphan receptor, c-myc transcription factor (puf), MHC-class IC | RNAs | Human | Upregulated in HCC than non-tumorous tissue ( with average ratio more than 2) | Diagnostic | HCC v/s non-tumor | NA | Tissue | 11283847 |
| 2526 | Plasminogen, Corticotropin releasing hormone bindingprotein, GRO2 oncogene, Interferon gamma-inducible protein 10, alpha-Platelet-derived growth factor receptor precursor, Cell division cycle 25C, Cytochrome P450-IIC, Human intercrine-a(hIRH), IL-8 | RNAs | Human | Downregulated in HCC than non-tumorous tissue ( with average ratio more than 2) | Diagnostic | HCC v/s non-tumor | NA | Tissue | 11283847 |
| 2527 | transgelin 2 | RNAs | Human | Upregulated in HCC than non-tumorous tissue | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15756260 |
| 2528 | B-factor | RNAs | Human | Downregulated in HCC than non-tumorous tissue | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15756260 |
| 2529 | HDAC2, PSMA7, PSMD1 | RNAs | Human | Upregulated in HCC than non-tumorous tissue | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15756260 |
| 2530 | HIMAP4, C5 | RNAs | Human | Downregulated in HCC than non-tumorous tissue | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15756260 |
| 2531 | TRIM25, EIF2S3, CLECSF14, DXYS155E, T-cell receptor beta locus, GIF2H2, SPON2, VDAC2, SLC15A3, HBP1, PTPRC, FES, CDC5L, ITGB2, MPP1, NDUFA2, AHCYL1, CNP, SQLE, RPA3, LGALS1, HLA-DQA1 , STMN1, PCOLCE, LOC387680, DPT, SLK, IGBP1, SNRPG, Human-alpha1-antitrypsin gene (S variant) complete cds, SIAHBP1, | RNAs | Human | 7 genes Downregulated i.e. CYP1A2, Human-alpha1-antitrypsin gene (S variant) complete cds, PCOLCE, CNP, DXYS155E, CLECSF14, TRIM25 and 29 get upregulated in | Diagnostic and prognostic | Single nodular HCC group v/s multicentric HCC group; associated with multicentric recurrence | p < 0.05 | Tissue | 16788756 |
| 2532 | GPC3, NCSTN, LCN2, PLK, PSK-1, PTTG1 | RNAs | Human | Upregulated in HCC than non-tumorous tissue | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15735714 |
| 2533 | PTMA | RNAs | Human | Upregulated in mt-p53 HCC than wt-p53 HCC and non-cancerous tissue (with Fisher ratios of >2.12) | Diagnostic | mutant-p53 HCC v/s wild type-p53 HCC and non-cancerous tissue | p < 0.01 | Tissue | 14675778 |
| 2534 | NUMA1 | RNAs | Human | Downregulated in mt-p53 HCC than wt-p53 HCC ; Upregulated in wt-p53 HCC than of non-cancerous liver (with Fisher ratios of >2.12) | Diagnostic | mutant-p53 HCC v/s wild type-p53 HCC and non-cancerous tissue | p < 0.01 | Tissue | 14675778 |
| 2535 | ADAR, PSMD4, D9SVA, CCT3, GBAP, RDBP, CSRP2, ILR7 | RNAs | Human | ILR-7 is Downregulated while others are Upregulated in | Prognostic | Moderately differentiated tumor (MD) v/s Well-differentiated tumor (WD) | p < 0.05 | Tissue | 12079511 |
| 2536 | AF147376, FLJ20084, LRP8, DKK2, AK027155, AK002039, PLSCR4, AK021998, ESDN, AKR7A2, MAP2K2, AL133075, APOL3, AK023559, GNRHR, COQ6, AF086143, FLJ14117, HUMCYT2A, D25272, M37712, KLK12, ZNF205, NM_001758, AK001102, KIAA0562, CIAO1, SRRM2, UBE1, FBXO10, AF113699, APOB, D86974, Z70704, SFRS2IP, WDFY1, | RNAs | Human | Discriminating among early-stage samples (between LGDN, HGDN and G1) | Prognostic | Dysplastic nodules of HCC v/s Edmondson grade 1 | p < 0.001 | Tissue | 16175600 |
| 2537 | SLC38A2, AF116620, MYO1B, SULT2A1, PRRG1, FLJ14153, C8A, HSPB7, UBE2D3, AF143323, CTH, L08441, DSIPI, NYD-SP21, AFG3L1, HGD, LRP8, SDHD, ALPL, HPX, AK022053, AK027242, RFX5, GALNT10, KIAA1671, NFKBIB, LOC149832, UACA, GNG10, AL110138, AK026168, INHBA, LAMP1, MLL5, MLLT6, Z36876, BDG29, FLJ12800, ARN | RNAs | Human | Discriminating among late-stage sample (between G1, G2 and G3) | Prognostic | Edmondson grade 1 HCC v/s Edmondson grade 2/3 HCC | p < 0.001 | Tissue | 16175600 |
| 2538 | ILF2, BMI1, TAF9, RFX5, SSRP1, ZNF146, SREBF2, MAFG, CHD4, NR4A1, ESR1, ZNF238, FOSB, ID1, FOS, H2AFY, SNRPB, RPS7, MRPS14, HNRPU, SNRPD2, NCL, RPS10, RPL6, SFPQ, DIM1, MARS, SFRS9, RBM3, U2AF65, SFRS1, SNRPE, SF3B4, RDBP, SNRPF, RRM1, RPL38, HNRPH1, U5-116KD, RPLP1, OXA1L, ADPRT, PRKDC, SMC4L1, H2A | RNAs | Human | Differentially Expressed in HCC Tumors than non-tumor (with fold change of 1.5) | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 15057898 |
| 2539 | NRCAM, CD24, CTHRC1, ROBO1, CENPM, FOXQ1, CDCA7L, MYBL2, PAFAH1B3, STK39, SPINK1, AKR1B10, SLC6A8, SOX4, | RNAs | Human | Upregulated in T3 than T1 and adjacent non-tumor (with 6 fold change) | Prognostic | Intrahepatic metastasis v/s primary HCC and normal | p < 0.05 | Tissue | 18504433 |
| 2540 | SOX4 | RNAs | Human | Upregulated in T3 than T1 and adjacent non-tumor (with 6 fold change) | Prognostic | Intrahepatic metastasis v/s primary HCC and normal | p < 0.05 | Tissue | 18504433 |
| 2541 | UCP2, MSR1, HPSE, CCL2, FCER1G | RNAs | Human | Downregulated in HCV-HCC carcinogenesis progression | Prognostic | HCV-HCC v/s early HCV cirrhosis, late HCV cirrhosis, and normal liver tissues | p < 0.05 | Tissue | 15108252 |
| 2542 | S100P, CD24, GPC3, DLK1, TM4SF3 | RNAs | Human | Upregulated in HCV-HCC carcinogenesis progression | Prognostic | HCV-HCC v/s early HCV cirrhosis, late HCV cirrhosis, and normal liver tissues. | p < 0.05 | Tissue | 15108252 |
| 2543 | TACSTD1, MYH4, PSPHL, CXCR4, N33, GMNN, MGP, RGS2, G1P2, AREG, EMP1, IFIT1, SPINK1, ADAMTS1, SLC2A3, EPHA3, GJA1, RDC1, KCNJ16, MX1, KRT23, THBD, MTHFD2, IFI44, IGF1, SGCE, SPARCL1, CYP3A5, ATP8B1 | RNAs | Human | Downregulated in late cirrhosis than early cirrhosis (with more than 3 fold) | Prognostic | Early v/s Late HCV Cirrhosis | p < 0.05 | Tissue | 15108252 |
| 2544 | SQLE, KIAA1919, ALDH4A1, NKTR, DICER1, C1QB, CYP2A6, EIF1AY, LPA, AKR1C4, GNMT, HLA-DRB4, IGFBP2, GPR88, MBD4, DEFA1, MADH1, HFR4, KIAA1847, FTHFD, SAA1, ASS, CRP, APOF, DBY, ATF5, RPS4Y, SAA2 | RNAs | Human | Upregulated in late cirrhosis than early cirrhosis (with more than 3 fold) | Prognostic | Early v/s Late HCV Cirrhosis | p < 0.05 | Tissue | 15108252 |
| 2545 | CDC42EP 4, IVNS1AB P, QTRT1, A2BP1, EDF1, ANXA2P3, ZNF706, STAT6, CDKN1C, DUSP6, PLOD1, ATP2A3, FAM65A, SIPA1, NCK2 | RNAs | Human | Downregulated in HCV-Cirrhosis with HCC than HCV-cirrhosis only (with fold change more than 1.3) | Prognostic | HCV-Cirrhosis v/s HCV-Cirrhosis with HCC | p < 0.05 | Tissue | 19098997 |
| 2546 | HLA-DR | Protein and RNAs | Human | Downregulated in HCC with early IHR vs. HCC without recurrence (with Fiser ratio 1.56) | Prognostic | Intrahepatic recurrence v/s Non-recurrence | p < 0.05 | Tissue | 15688398 |
| 2547 | FBN1, MEF2C, TNFAIP3, LAPTM5, TMSB4X, CUGBP2, HLA-DRA, REL, clone110298, LTBP2, TRIM22, HLA-DRBI, FOXF1, HLA-DQA, SDF1, DDX17, SGK, PDGFRA, F2R, HLADG, MTAP44, CTSK, VIM, ACVR1, ON/SPARC, SCYA3, ARHGEF6, CCND2, COL1A1, ITGB2/CD18, PTPRC, MKNK1, JUNB, EST, GATA6, FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP | RNAs | Human | 11 genes (FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP, FUT1, GCHFR, CYP2A, MLH1, EST) Upregulated and rest 35 genes downregulated in HCC with early IHR vs. HCC without recurrence | Prognostic | Intrahepatic recurrence v/s Non-recurrence | p < 0.05 | Tissue | 15688398 |
| 2548 | PCNA | Protein | Human | Upregulated in HCC than non-HCC (avg ratio HCC to non-tumor 9.1 +/- 5.4) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15759316 |
| 2549 | Stathmin 1 | Protein | Human | Upregulated in HCC than non-HCC (avg ratio HCC to non-tumor 11.1 +/- 15.7) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15759316 |
| 2550 | FGG | Protein | Human | Upregulated in well-differentiated HCC (with 2 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15852300 |